Stock Analysis

Uni-Bio Science Group Full Year 2024 Earnings: EPS: HK$0.014 (vs HK$0.011 in FY 2023)

SEHK:690
Source: Shutterstock

Uni-Bio Science Group (HKG:690) Full Year 2024 Results

Key Financial Results

  • Revenue: HK$553.0m (up 14% from FY 2023).
  • Net income: HK$82.8m (up 17% from FY 2023).
  • Profit margin: 15% (in line with FY 2023).
  • EPS: HK$0.014 (up from HK$0.011 in FY 2023).
earnings-and-revenue-history
SEHK:690 Earnings and Revenue History March 31st 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Uni-Bio Science Group shares are down 4.2% from a week ago.

Risk Analysis

It's still necessary to consider the ever-present spectre of investment risk. We've identified 1 warning sign with Uni-Bio Science Group, and understanding this should be part of your investment process.

If you're looking to trade Uni-Bio Science Group, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.

With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.

Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.

Sponsored Content

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About SEHK:690

Uni-Bio Science Group

An investment holding company, researches and develops, manufactures, and sells biological and chemical pharmaceutical products to treat human diseases in the People’s Republic of China.

Solid track record with excellent balance sheet.